Oral contraceptives and venous thromboembolism: An epidemiological review

European Journal of Contraception and Reproductive Health Care

Volumn 1, Issue 1, 1996, Pages 13-20

  Lidegaard, O ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Confounding; Epidemiology; Oral contraceptives; Prescribing bias; Risk factors; Selection bias; Venous thromboembolism

Indexed keywords

DESOGESTREL; GESTODENE; LEVONORGESTREL; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PREGNANE DERIVATIVE; PROGESTERONE DERIVATIVE;

CHEMICALLY INDUCED DISORDER; CHEMISTRY; EPIDEMIOLOGY; FEMALE; HEART INFARCTION; HUMAN; METHODOLOGY; PATIENT SELECTION; REVIEW; THROMBOEMBOLISM;

CAUSALITY; CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; FEMALE; HUMANS; LEVONORGESTREL; MYOCARDIAL INFARCTION; NORGESTREL; NORPREGNENES; PATIENT SELECTION; PROGESTERONE CONGENERS; RESEARCH DESIGN; SELECTION BIAS; THROMBOEMBOLISM;

EID: 0030088984     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.3109/13625189609150651     Document Type: Review

References (26)

1. World Health Organization Collaborative Study on cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82
2. World Health Organization Collaborative Study on cardiovascular disease and steroid hormone contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8
3. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6
4. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93
5. Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83-7
6. Lewis MA, Spitzer WO, Heinemann LAJ, et al. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Br Med J 1996; 312: 88-90
7. Inman WHW, Vessey MA. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Br Med J 1968; 2: 193-9
8. Vessey MA, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J 1968; 2: 199-205
9. Vessey MA, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Br Med J 1969; 2: 651-7
10. Royal College of General Practitioners' Oral Contraception Study. Oral contraceptives, venous thrombosis, and varicose veins. J R Coll Gen Pract 1978; 28: 393-9
11. Petitti DB, Winger J, Pellegrin F, et al. Risk of vascular disease in women. J Am Med Assoc 1979; 242: 1150-4
12. Porter JB, Hunter JR, Damelson DA, et al. Oral contraceptives and nonfatal vascular disease - recent experience. Obstet Gynecol 1982; 59: 299-302
13. Overgaard K, Hauch O, Lidegaard O. Venous thromboembolic disease and oral contraceptives. Ugeskr Laeger 1986; 148: 2348-50
14. Vessey M, Mant D, Smith A, et al. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J 1986; 292: 526
15. Gerstman BB, Piper JM, Freiman JP, et al. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol 1990; 19: 931-6
16. Thorogood M, Mann J, Murphy M, et al. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992; 21: 48-52
17. Farmer R, Preston TD. The risk of venous thromboembolism associated with low oestrogen oral contraceptives. J Obstet Gynaecol 1995; 15: 195-200
18. Farmer R. Lancet 1996; 347: 259
19. Lidegaard O, Milsom I. The pill. The controversy continues. Acta Obstet Gynecol Scand 1996; 75: 93-7
20. Lidegaard O, Milsom I. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception 1996; 53: 135-9
21. Sartwell PE, Masi AT, Arthes FG, et al. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol 1969; 90: 365-80
22. Böttiger LE, Boman G, Eklund G, et al. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980; 1: 1097-101
23. Böttiger LE, Westerholm B. Oral contraceptives and thromboembolic disease. Acta Med Scand 1991; 190: 455-63
24. CPMP. Position statement of the CPMP on oral contraceptives containing desogestrel or gestodene. The European Agency for the Evaluation of Medicinal Products. London, April, 1996
25. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. Br Med J 1993; 306: 956-63
26. Hannaford PC, Croft PR, Kay CK. Oral contraception and stroke. Evidence from the Royal College of General Practitioners' Oral Contraception Study. Stroke 1994; 25: 935-42